AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05289856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: combination of Avelumab and Cabozantinib
Description: Cabozantinib 40 mg daily PO in combination with Avelumab at a dose of 800 mg as a 1h intravenous (i.v.) infusion every two weeks (q2w) until disease progression (PD), unacceptable toxicity, or any criterion for treatment withdrawalis met, for a maximum of 12 months
Study NCT05550883 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: The patients in this group participated in aerobic exercise training for 45 minutes, three sessions per week for 6 weeks. They underwent the proper warm up to minimize the risk of musculoskeletal injury .The training session started by a proper warm up for 5 min in the form of mild stretching for the involved muscle group to prepare the exercised muscles and improve blood supply for skeletal muscle to prevent fatigue or injury. Patients in this study group performed aerobic exercise (in the form of treadmill training) All sessions were supervised to ensure correct technique and monitor the appropriate amount of exercise. The training session ended by a proper cooling down for 5 min to prevent fatigue or injury.
Study NCT05550883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fibromyalgia Agents
Description: tricyclic antidepressants (low evening doses), and mostly when needed, low doses of: analgesics, muscle relaxants, hypnotics, and tranquilizers.
Study NCT05550883 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fibromyalgia Agents
Description: tricyclic antidepressants (low evening doses), and mostly when needed, low doses of: analgesics, muscle relaxants, hypnotics, and tranquilizers.
Study NCT04565613 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Enteral protein supplementation
Description: The participants in the study interventional group will receive protein supplementation to reach a final goal of 1.5 g/kg/day of protein on full feeds. This will be via 100% whey protein isolate (Nestle Beneprotein). Doses will be calculated on the patient's admission weight and rounded up to the nearest 1g. Doses will not be adjusted to account for weight changes in the PICU.~Protein supplementation will continue for a total of 7 days from the start of enrolment into the study or until PICU discharge, whichever is earlier. If the patient is able to take solid feeds during the study intervention period, the intervention will be stopped. However, if the device required for feeding is removed but the patient takes milk/liquid feeds fully, protein supplementation will continue.
Study NCT04776564 — intervention group
Intervention type: OTHER
Intervention: Participation in the couple enhancement program
Description: Participation in a 12 hour long couple enhancement program called Gottman seven principles (G7P)
Study NCT05445518 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Jump Start Plus COVID Support
Description: The Jump Start Plus COVID Support intervention is a resiliency program that provides behavior management and safety programs administered weekly via zoom.
Study NCT05701553 — intervention group
Intervention type: DRUG
Intervention: Anti-PD-1/PD-L1
Description: Intravenous injection at indicated dose for at least 6 months
Study NCT05701553 — intervention group
Intervention type: DRUG
Intervention: S-Adenosyl-Methionine
Description: Taken orally at indicated dose for at least 6 months
Study NCT04414553 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Active and Healthy Families
Description: Community-AHF will consist of eight, semimonthly 2-hour group appointments. Community-AHF sessions will target two areas: 1) Practical information regarding importance of healthy behaviors, and 2) Problem-solving skills to overcome barriers to improving diet and increasing physical activity and other related healthy behaviors. Each session covers specific objectives, includes a number of complementary activities and provides participants with take-home materials to facilitate behavior change.~Community-AHF will be delivered by a nurse and a Community Health Worker (CHW) trained by a consultant nutritionist and study investigators. The CHW will contact families between group sessions to discuss challenges and successes regarding lifestyle changes.
Study NCT04966234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole 100 MG [Noxafil]
Description: Posaconazole is a lipophilic, highly permeable triazole, which is practically insoluble in water. Posaconazole inhibits the enzyme CYP51a (also known as Erg11p or lanosterol demethylase). This enzyme is required for catalysation of an essential step in biosynthesis of ergosterol in filamentous fungi and yeasts.~Posaconazole is favoured over itraconazole and voriconazole with respect to palatability, tolerability and toxicity profile
Study NCT04966234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole 40 MG/ML
Description: Posaconazole is a lipophilic, highly permeable triazole, which is practically insoluble in water. Posaconazole inhibits the enzyme CYP51a (also known as Erg11p or lanosterol demethylase). This enzyme is required for catalysation of an essential step in biosynthesis of ergosterol in filamentous fungi and yeasts.~Posaconazole is favoured over itraconazole and voriconazole with respect to palatability, tolerability and toxicity profile
Study NCT05710250 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 6-week MBSR program
Description: Participants will follow a 6-week program of mindfulness meditation. MBSR teaches mindfulness meditation and mindful yoga exercises to develop non-judgmental awareness of moment-to-moment experience. The intervention duration is 6 weeks, with weekly two and half hours sessions. It will be delivered according to the fundamental concepts and specific techniques provided in the MBSR manualized protocol by Kabat-Zinn. The program also includes 30-min daily homework exercises.~MBSR teaches four main mindfulness practices: (1) body scan, a process of moving attention through the body; (2) mindful movement, consisting of gentle yoga stretches to develop awareness of body in movement; (3) sitting meditation; and (4) walking meditation. Inquiry and didactic teaching is also a part of MBSR and allows for some detailed exploration of participants' experiences.
Study NCT05710250 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 6-week muscular relaxation program
Description: Control group : This group will follow a 6-week program of progressive muscle relaxation training in order to learn achieving a deep relaxation of the body through voluntary tensing and relaxing muscles. It proceeds by the individual sequentially tensing and then releasing specific groups of muscles throughout the body, and noticing how tension feels relative to relaxation.~The accomplishment of physical relaxation promotes mental calmness in a parallel manner. This program is based on the work of Bernstein and Borkovec and Jacobson, and will be structured in 6-week group with weekly two and half hours sessions and out-of-session assignments for at-home practice (30-min daily).
Study NCT06159283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunoglobulins
Description: Dosage is Immunoglobulin 1,000mg/kg IV. It administer over 2\~3 days.
Study NCT00057057 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Telephone Care
Study NCT05445518 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Caregivers-Healthy Children (HC2)
Description: The HC2 intervention is an obesity prevention program that provides nutrition and healthy activities programs administered weekly via Zoom.
Study NCT05110781 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV
Study NCT05110781 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study NCT05110781 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study NCT05171972 — intervention group
Intervention type: DRUG
Intervention: Ofatumumab
Description: This investigator-initiated study will be carried out secondary to the discussion of treatment with Ofatumumab and thus our study will not influence or impact the determination of the suitability for candidates to commence therapy with Ofatumumab. This decision will be made by the patient's physician as part of the patient's standard care, and will occur independently of this study. Patients to be enrolled in this longitudinal study will only be asked if they would like to take part if their clinician independently chooses Ofatumumab as a treatment option.
Study NCT05831527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARMRA™ Bovine Colostrum
Description: Participants have the option to choose between unflavoured ARMRA™ Bovine Colostrum or blood orange flavoured ARMRA™ Bovine Colostrum.~Participants took 2 sachets (1g each) of the product mixed with a cold drink daily for 12 weeks.
Study NCT05402254 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacovigilance Program
Description: Knowledge of the risks in the use of the drug, identification and notification of ADE
Study NCT06351826 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ELLASI
Description: A structured intervention for polytrauma patients
Study NCT06351826 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard
Description: Unstructured interventions that are given in everyday practice (standard intervention)
Study NCT05370365 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Below elbow cast
Description: Patients will be stay with a below elbow cast for 4 or 6 weeks
Study NCT06337981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (AJU-S56 5% and placebo)
Description: (AJU-S56 5%) and placebo(Vehicle), 1drop/1times, 3times in a day
Study NCT06337981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AJU-S56 5%
Description: (AJU-S56 5%), 1drop/1times, 6times in a day
Study NCT06337981 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo(Vehicle)
Description: Placebo(Vehicle), 1drop/1times, 6times in a day
Study NCT05881707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-828, D064, D702
Description: QD, PO
Study NCT04883255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg Δ9-tetrahydrocannabinol (THC)
Description: 5-day course of orally-administered THC (dronabinol), 10 mg
Study NCT04883255 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10 mg Δ9-tetrahydrocannabinol (THC)
Description: 5-day course of orally-administered THC (dronabinol), 10 mg
Study NCT04883255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 600 mg cannabidiol (CBD)
Description: 5-day course of orally-administered CBD, 600 mg
Study NCT04883255 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 600 mg cannabidiol (CBD)
Description: 5-day course of orally-administered CBD, 600 mg
Study NCT04883255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 5-day course of orally-administered placebo
Study NCT04883255 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 5-day course of orally-administered placebo
Study NCT05406128 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: preoperative erector spina plane block
Description: Erector spina plane block will be applied to preoperative group patients in the preoperative period.
Study NCT05406128 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: intraoperative erector spina plane block
Description: In the intraoperative group, erector spina plane block will be applied after anesthesia induction.
Study NCT06184191 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Robotic hand rehabilitation
Description: Robotic hand rehabilitation devices are the most advanced, effective and user-friendly combination of technology to support motor rehabilitation of the upper limb and neurocognitive recovery. Serving patients, doctors, therapists through therapies and protocols that accompany all stages of the rehabilitation process, the devices promote the functional recovery of patients and their reintegration into daily life.
Study NCT06184191 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Robotic hand rehabilitation
Description: Robotic hand rehabilitation devices are the most advanced, effective and user-friendly combination of technology to support motor rehabilitation of the upper limb and neurocognitive recovery. Serving patients, doctors, therapists through therapies and protocols that accompany all stages of the rehabilitation process, the devices promote the functional recovery of patients and their reintegration into daily life.
Study NCT06457477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: 100mg/10ml/1bottle
Study NCT06457477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NAs
Description: tablets
Study NCT06457477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-IFNα-2b
Description: 180ug/0.5ml/1bottle
Study NCT06011265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myrbetriq 25Mg Extended-Release Tablet
Description: Participants take 4x 25mg Myrbetriq 25Mg Extended-Release Tablet orally.
Study NCT06011265 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants take empty capsule orally
Study NCT06199765 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Needlestick Injury Prevention
Description: this intervention will be using needlestick injury prevention module which will involve lecture, demonstration, and role play
Study NCT06199765 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Needlestick Injury Prevention
Description: this intervention will be using needlestick injury prevention module which will involve lecture, demonstration, and role play
Study NCT06716541 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERCP implantation of a biodegradable stent
Description: Endoscopic retrograde cholangiopancreatography (ERCP) with placement of a biodegradable stent to treat anastomotic biliary stricture (possibly combined with removal of previous plastic stents).
Study NCT06716541 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERCP implantation of plastic stents
Description: Endoscopic retrograde cholangiopancreatography (ERCP) with placement of a plastic stent or multiple stents to treat anastomotic biliary stricture (possibly combined with removal of previous plastic stents).
Study NCT06716541 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ERCP implantation of plastic stents
Description: Endoscopic retrograde cholangiopancreatography (ERCP) with placement of a plastic stent or multiple stents to treat anastomotic biliary stricture (possibly combined with removal of previous plastic stents).
Study NCT06717620 — intervention group
Intervention type: BEHAVIORAL
Intervention: Body composition before and after exams
Description: Measurement of body composition, eating habits, physical exercise in the same group of students before and after the exams
Study NCT06718881 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: simulation application in a virtual reality environment
Description: In the project, theoretical lessons were given on preeclampsia, postpartum care, and condom counseling, each in a separate week. After each theoretical lesson, an application was made in the laboratory on the subject explained in the same week. The applications were made in the form of a simulation application in a virtual reality environment for the students in the experimental group.
Study NCT05460650 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App Promoting Healthy Behaviours
Description: Women on the study will receive two months access to the app.
Study NCT05632029 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active laser
Description: 32 lupus prediabetic women will receive laser acupuncture (active laser) for one month (3 days week) on acupoint number 14 of GV meridian, acupoint number 4 and 11 of large intestine, acupoint number 34 of gall bladder meridian, acupoint number 3 of liver meridian, acupoint number 4, 12, and 9 of conception vessel meridian, acupoint number 40, 36, and 25 of stomach meridian, acupoint number 6 of spleen meridian, and acupoint number 5 of triple energizer meridian, laser will be applied for 1 min on every acupiont)
Study NCT05632029 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham laser
Description: 32 lupus prediabetic women will receive laser acupuncture (sham laser, i.e power of device will be zero watt) for one month (3 days week) on acupoint number 14 of GV meridian, acupoint number 4 and 11 of large intestine, acupoint number 34 of gall bladder meridian, acupoint number 3 of liver meridian, acupoint number 4, 12, and 9 of conception vessel meridian, acupoint number 40, 36, and 25 of stomach meridian, acupoint number 6 of spleen meridian, and acupoint number 5 of triple energizer meridian, laser will be applied for 1 min on every acupiont)
Study NCT05082298 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dental FearLess app
Description: Dental FearLess, is a self-administered psychoeducational intervention that will be accessed by participants via their personal smart device (In other words, this is an online application in which investigators present information about dental procedures. The user selects the procedure on which they would like information and then views a brief video on the selected procedure. It uses evidence-based tools to help participants manage their thoughts, feelings, and behavior related to dental fear to reduce fear during encounters with dental professionals.
Study NCT05082298 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-Chair Treatment Protocol
Description: This session is a 1-hour-in-person Cognitive Behavioral Therapy (CBT) dental fear session by study staff at the dental office. Participants will practice managing their thoughts, behaviors, and/or feelings when exposed to stimuli that they report still fearing. After each practice situation, the mental health provider and participant discuss the disconfirmatory evidence generated by the situation.
Study NCT04670224 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: QLB anesthesia
Description: The QLB is a bilateral locoregional anesthesia technique, performed after surgery, under general anesthesia and in right and then left lateral decubitus.
Study NCT04670224 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous anesthesia without QLB
Description: only intravenous anesthesia
Study NCT06335420 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Carrot juice from Yellowstone carrots cultivars
Description: Consumption of 100 ml of carrot juice daily for 1 year
Study NCT06335420 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo juice
Description: Consumption of 100 ml of placebo juice daily for 1 year
Study NCT04776421 — intervention group
Intervention type: PROCEDURE
Intervention: Diverting ileostomy
Description: Diverting ileostomy
Study NCT06041685 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: local warming
Description: local warming on the site for arterial catheterization using forced air warmer
Study NCT05264558 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xpert HCV Viral load finger stick point of care test (Cepheid)
Description: Xpert HCV VL Fingerstick is an in vitro reverse transcription polymerase chain reaction (RT-PCR) assay for the detection and quantification of Hepatitis C Virus (HCV) RNA in human venous and capillary fingerstick EDTA whole blood. Appropriate pre and post testing counselling will be provided to participants.
Study NCT05264558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epclusa 400Mg-100Mg Tablet
Description: Same day HCV test and treatment
Study NCT05264558 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Description: Clinical services will receive additional education and have the option of providing incentives to attendees of service.
Study NCT05755997 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cerebrolysin
Description: 40 ml Cerebrolysin and 60 ml 0.9% NaCl per day for 4 days every month for 1 year
Study NCT05755997 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 0.9 % NaCl
Description: 100 ml 0.9% NaCl per day for 4 days every month for 1 year
Study NCT05505097 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Hydroxymethylquinoxalindioxyde
Description: Dioxidin (Hydroxymethylquinoxalindioxyde), solution for topical and external use, 0.25 mg/ml, applied as:~A - single rinsing of the oropharynx with 15.0 ml of the drug solution for at least 30 seconds B - single irrigation of the oropharynx by spraying the preparation 4 times with a spray nozzle C - irrigation of the skin on the back by spraying the preparation 4 times from a distance of 10 cm on 1% of the body surface using a spray nozzle and exposing the solution for 30 minutes or D - Dioxidin (Hydroxymethylquinoxalindioxyde), solution for infusion and external application, 5 mg/ml, single intravenous 5 mg/ml in 1 ml